Pascal Brière – President, Biogaran, France
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Address: 15 bd Charles de Gaulle 92707 Colombes ,France
Tel: +33 (0)1 55 72 41 00
Biogaran, is an independent French laboratory focused on generic drugs and was born in 1996 at the initiative of the first independent French pharmaceutical group: Servier.
Today the group is second on the French market and produces 55% of its products within the country. The laboratory Biogaran has commissioned the Social Security savings of around € 1 billion since its inception in 1996.
The group distributes a wide variety of pharmaceutical medications through French pharmacies
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Biogaran was an initiative from Servier in the mid 1990s before there was even a generic pharmaceutical market in France. Could you speak of your history and of the origins…
The President of Innothera talks about their unique business model, being in both the drug production and compression stockings businesses, how almost 95 percent of their drug production is exported,…
Olivier Pilley, French GM of the Swiss-American biotech company with a pioneering computational approach to anti-cancer therapies, presents ARIAD’s fascinating R&D model, his optimistic assessment of the competitiveness of the French…
The Director of the Social Security talks about the need to strengthen the sustainability of the French social security system, how France is attached to its unique system combining a…
The head of Aspen sterile operations and managing director of Aspen NDB, reveals how their facility in France acts as the main platform for the group´s sterile business, a market…
The CEO of Diaxonhit Group, a fully integrated French leader in in vitro diagnostics, discusses the company’s strategic focus on specialty vitro diagnostics, his perspective on the challenge of consolidation…
The Vice President of Health and Medicine at Pierre and Marie Curie University (UPMC) and Director of the University’s Institute of Oncology reveals how the French social security system needs…
The Director of the CNCR and the person in charge of the industrial sector, talk about the fragmented nature of French clinical research funding, why when it comes to boosting…
The President of France’s Association for CROs (AFCROs) discusses the issues surrounding France’s clinical research sector and the actions that both the public and private sector need to take to…
The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership…
Pierre Banzet, President of Group Synerlab, one of the top ten French CMOs, discusses his group’s ambitious European expansion strategy, driven by their specialties in multi-dose, preservative-free eye drops, generics,…
The Director of the newly formed Necker Institute for Sick Children reveals how the inspiration behind INEM was to bring people together in order to create a common scientific policy…
Pfizer Global Established Products’ BU Head and Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well…
See our Cookie Privacy Policy Here
